Abstract
Tau proteins are markers of different pathological conditions, such as hypoxia, different types of stress and degenerative processes observed in nerve cells, glial cells or muscle fibers. Tau proteins are the basic components of the pathological filaments that accumulate in neurons and glial cells affected by neurofibrillary degeneration’. Tau pathology is observed in more than 20 different diseases, including Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick’s disease (PiD), myotonic dystrophy (MyoD), familial frontotemporal dementias with Parkinsonism associated to chromosome 17 (FTDP-17), etc. Tau is an outstanding marker well correlated with clinical manifestations. Indeed, pathological tau proteins observed in the association neocortical areas are systematically associated with dementia. Together, tau pathology reveals precisely the intensity and the extent of the degenerating process. This pathological entity can be defined according to 6 different molecular parameters that are presented here.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Buée L, Bussière T, Buée-Scherrer V et al. (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev: in press.
Delacourte A, Buée L (2000) Tau pathology: a marker of neurodegenerative disorders. Current Opinion in Neurology: in press.
Buée-Scherrer V, Condamines O, Mourton-Gilles C et al. (1996) AD2, aphosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer’s disease. Brain Res Mol Brain Res 39: 79–88.
Sergeant N, Wattez A, Delacourte A (1999) Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively “exon 10” isoforms. J Neurochem 72: 1243–1249.
Mulot SF, Hughes K, Woodgett JR et al. (1994) PHF-tau from Alzheimer’s brain comprises four species on SDS-PAGE which can be mimicked by in vitro phosphorylation of human brain tau by glycogen synthase kinase-3 beta. FEBS Lett 349: 359–364.
Flament S, Delacourte A, Verny M et al. (1991) Abnormal Tau proteins in progressive supranuclear palsy. Similarities and differences with the neurofibrillary degeneration of the Alzheimer type. Acta Neuropathol 81: 591–596.
Delacourte A, Sergeant N, Wattez A et al. (1998) Vulnerable neuronal subsets in Alzheimer’s and Pick’s disease are distinguished by their tau isoform distribution and phosphorylation. Ann Neurol 43: 193–204.
Vermersch P, Sergeant N, Ruchoux MM et al. (1996) Specific tau variants in the brains of patients with myotonic dystrophy. Neurology 47: 711–717.
Mailliot C, Sergeant N, Bussière T et al. (1998) Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes. FEBS Lett 433: 201–204.
Conrad C, Andreadis A, Trojanowski JQ et al. (1997) Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol 41: 277–281.
Evans DB, Rank KB, Bhattacharya K et al. (2000) Tau phosphorylation at Serine-396 and Serine-404 by human recombinant tau protein kinase II inhibits tau’s ability to promote microtubule assembly. J Neurosci 20: 3937–3946.
Matsuo ES, Shin RW, Billingsley ML et al. (1994) Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer’s disease paired helical filament tau. Neuron 13: 989–1002.
Sergeant N, Bussière T, Vermersch P et al. (1995) Isoelectric point differentiates PHFtau from biopsy-derived human brain tau proteins. Neuroreport 6:2217–2220.
Bussière T, Hof PR, Mailliot C et al. (1999) Phosphorylated serine422 on tau proteins is a pathological epitope found in several diseases with neurofibrillary degeneration. Acta Neuropathol 97: 221–230.
Probst A, Tolnay M, Langui D et al. (1996) Pick’s disease: hyperphosphorylated tau protein segregates to the somatoaxonal compartment. Acta Neuropathol 92:588–596.
Cairns NJ, Atkinson PF, Hanger DP et al. (1997) Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer’s disease. Neurosci Lett 230: 49–52.
Delacourte A, David JP, Sergeant N et al. (1999) The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease. Neurology 52: 11581165.
Working Group (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. Neurobiol Aging 18: SI-2.
Vermersch P, Robitaille Y, Bernier L et al. (1994) Biochemical mapping of neurofibrillary degeneration in a case of progressive supranuclear palsy: evidence for general cortical involvement. Acta Neuropathol 87: 572–577.
Buée Scherrer V, Hof PR, Buée L et al. (1996) Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick’s disease. Acta Neuropathol 91:351359.
Delacourte A (2000) The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease. Neurology 54: 538.
Sahara N, Tomiyama T, Mori H (2000) Missense point mutations of tau to segregate with FTDP-17 exhibit site-specific effects on microtubule structure in COS cells: A novel action of R406W mutation. J Neurosci Res 60: 380–387.
Conrad C, Amano N, Andreadis A et al. (1998) Differences in a dinucleotide repeat polymorphism in the tau gene between Caucasian and Japanese populations: implication for progressive supranuclear palsy. Neurosci Lett 250: 135–137.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Delacourte, A. (2001). The Molecular Parameters of Tau Pathology. In: Tolnay, M., Probst, A. (eds) Neuropathology and Genetics of Dementia. Advances in Experimental Medicine and Biology, vol 487. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1249-3_2
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1249-3_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5461-1
Online ISBN: 978-1-4615-1249-3
eBook Packages: Springer Book Archive